Goldman Sachs Upgrades Rocket Pharmaceuticals (NASDAQ: RCKT) Amid Gene Therapy Progress and Financing

• Goldman Sachs Upgrade: Goldman Sachs upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Sell to Neutral, reflecting a more balanced outlook on the gene therapy company.
• Strategic Financing: Rocket Pharmaceuticals secured a $150 million credit facility from Hercules Capital to fund its pivotal Phase 2 Danon disease trial and broader cardiovascular pipeline.
• Positive Clinical Trial Data: Early safety findings from Rocket's Phase 2 trial for RP-A501 in Danon disease showed no serious complications in initial patients, indicating a defined path to trial completion and potential FDA approval.

Goldman Sachs upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) to Neutral from Sell when the gene therapy stock was trading at $2.54. Rocket develops innovative gene therapies for serious diseases, including Danon disease, a condition that affects the heart. The upgrade moves Goldman's rating from a negative view to a more balanced one, signaling potential for Rocket's stock performance.

Rocket has secured access to up to $150 million through a credit facility with Hercules Capital, as highlighted by Proactive Investors. A credit facility lets a company borrow funds under an agreed arrangement. Rocket says the financing will support its pivotal Phase 2 study of RP-A501 for Danon disease and its broader cardiovascular pipeline, bolstering its biotechnology research and development.

Rocket also reports a defined path to complete its FDA-aligned Phase 2 trial, as highlighted by Business Wire. The first three patients treated under a modified trial protocol completed an initial observation period without clinical or laboratory evidence of two serious complications: thrombotic microangiopathy or capillary leak syndrome. Follow-up continues, so these early safety findings remain preliminary, but are crucial for regulatory approval.

The shares of Rocket rose 4% Wednesday after the financing news. In a separate trading update, Rocket was at $2.54, up $0.06, or 2.22%. Its 52-week range was $2.42 to $5.45, with a market value of about $277 million and trading volume of about 2.81 million shares. This reflects the market's reaction to the positive developments for the pharmaceutical company.